` 095700 (Genexine Inc) vs KOSPI 200 Comparison - Alpha Spread

G
095700
vs
K
KOSPI 200

Over the past 12 months, Genexine Inc has underperformed KOSPI 200, delivering a return of -13% compared to the KOSPI 200's +76% growth.

Stocks Performance
095700 vs KOSPI 200

Loading
095700
KOSPI 200
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
095700 vs KOSPI 200

Loading
095700
KOSPI 200
Difference
www.alphaspread.com

Performance By Year
095700 vs KOSPI 200

Loading
095700
KOSPI 200
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Genexine Inc vs Peers

KOSPI 200
095700
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Genexine Inc
Glance View

Market Cap
219B KRW
Industry
Biotechnology

Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2009-09-15. The firm operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. The company also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.

Intrinsic Value
326.45 KRW
Overvaluation 93%
Intrinsic Value
Price
G
Back to Top